Reduce the rate of potentially hazardous prescribing, focus on the safer use of non-steroidal anti-inflamatory drugs (NSAIDs) in patients at significant risk of complications such as gastrointestinal bleeding.

Better monitoring of potentially toxic medications and the creation of safe systems to support drug monitoring through a focus on lithium prescribing (or another agreed medication if no patients on the registered list are currently being prescribed lithium).

Better engagement of patients with their medication through a focus on valproate and pregnancy prevention.

Improve collaboration between practices, networks and community pharmacists to share learning and improve systems to reduce harm and improve safety.

Participate in a minimum of 2 network peer review meetings.

Early identification and support for people with advanced progressive illness who might die within the next 12 months.

Well-planned and coordinated care that is responsive to the patient’s changing needs with the aim of improving the experience of care.

Identification and support for family/informal caregivers, both as part of the core care team around the patient and as individuals facing impending bereavement.

Participate in a minimum of 2 network peer review meetings.